Results 151 to 160 of about 20,614 (289)

Effect of sacubitril/valsartan on lipid metabolism in patients with chronic kidney disease combined with chronic heart failure: a retrospective study

Lipids in Health and Disease
Background and objective Dyslipidemia is significantly more common in those with concurrent chronic kidney disease (CKD) and chronic heart failure (CHF).
Manzhi Li, Ao Zhong, Yifan Tang, Jinnuo Yu, Mengmeng Wu, Karthick Kumaran Munisamy Selvam, Dong Sun   +6 more
semanticscholar   +1 more source

Pharmacophore‐Based Identification and Molecular Characterization of Potent Neprilysin Inhibitors: Biochemical and Therapeutic Implications for Cardiovascular Diseases

Chemical Biology &Drug Design, Volume 107, Issue 2, February 2026.
Pharmacophore‐based virtual screening and molecular dynamics identified pentagalloylglucose and tannic acid as potent, non‐toxic neprilysin inhibitors. These natural compounds demonstrated strong binding affinity and stable interactions with the catalytic Zn2+ site, offering promising leads for cardiovascular drug development. ABSTRACT Neprilysin (NEP),
Chung‐Ting Kuo, Yi‐Chen Wu, Ji‐Min Li, Tz‐Chuen Ju, Tien‐Sheng Tseng   +4 more
wiley   +1 more source

Sacubitril Does Not Exert Proarrhythmic Effects in Combination with Different Antiarrhythmic Drugs

Pharmaceuticals
Background: Previous studies suggest a direct effect of sacubitril on cardiac electrophysiology and indicate potential arrhythmic interactions between sacubitril and antiarrhythmic drugs.
Christian Ellermann, Carlo Mengel, Julian Wolfes, Felix K. Wegner, Benjamin Rath, Julia Köbe, Lars Eckardt, Gerrit Frommeyer   +7 more
doaj   +1 more source

Sacubitril/valsartan improved microvascular endothelial function in a young patient with COVID-19-related mild left ventricular dysfunction

, 2022
Marcin Hellmann, Edyta Dąbrowska, Marta Żarczyńska-Buchowiecka, Marzena Romanowska-Kocejko, Krzysztof Narkiewicz, Marcin Gruchała, Maria Dudziak   +6 more
openalex   +2 more sources

Devastating Worsening Renal Function Following the Initiation of Sacubitril/Valsartan: Falling Between Two Stools [PDF]

, 2023
Akinori Sairaku, Yukiko Nakano
openalex   +1 more source

Újdonságok a krónikus szívelégtelenség gyógyszeres terápiájában | Novelties in the pharmacological treatment of chronic heart failure [PDF]

, 2016
Absztrakt A krónikus szívelégtelenség gyógyszeres kezelését illetően számos új vizsgálat eredményét publikálták az elmúlt években, és 2016-ban megjelent az Európai Kardiológiai Társaság (ESC ...
Nyolczas, Noémi
core   +1 more source

Sacubitril/valsartan ameliorates cardiac function and ventricular remodeling in CHF rats via the inhibition of the tryptophan/kynurenine metabolism and inflammation

Scientific Reports
Sacubitril/valsartan has been highly recognized as a treatment for Chronic heart failure (CHF). Its potential cardioprotective benefits and mechanisms, however, remain to be explored. Metabolomics can be used to identify the metabolic characteristics and
Jiali Gan, Yuli Wang, Yun Deng, Jiaqi Zhang, Shuangcui Wang, Xijuan Jiang, Maojuan Guo, Lili Song   +7 more
semanticscholar   +1 more source

Inibitori della neprilisina nel trattamento dell'insufficienza cardiaca : basi farmacologiche ed evidenze cliniche per l'associazione Sacubitril+Valsartan [PDF]

, 2016
Lo scompenso cardiaco è una sindrome multifattoriale nella quale un evento cronico come l'ipertensione, oppure un evento acuto come l'infarto , sono responsabili di alterazioni funzionali che impediscono al cuore di espellere sangue sufficiente da ...
PERONDI, MICHELE
core  

The Benefits of Sacubitril–Valsartan in Patients with Acute Myocardial Infarction: A Systematic Review and Meta-Analysis

, 2021
Bo Xiong, Dan Nie, Jun Qian, Yuanqing Yao, Gang Yang, Shunkang Rong, Que Zhu, Yun Du, Yonghong Jiang, Jing Huang   +9 more
openalex   +1 more source

Real-life effectiveness of sacubitril/valsartan in older Belgians with heart failure, reduced ejection fraction and most severe symptoms

Scientific Reports
We assessed the real-world effectiveness of sacubitril/valsartan in patients with chronic heart failure (HF) and reduced ejection fraction (HFrEF) with an emphasis on those with older age (≥ 75 years) or with New York Heart Association (NYHA) class IV ...
E. Maury, A. Belmans, Kris Bogaerts, Stefaan Vancayzeele, Mieke Jansen   +4 more
semanticscholar   +1 more source